Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PLRZ

Polyrizon Ltd

Apr 30 • 03:33PM ET

15.83

+0.11 0.70 %

Healthcare • Biotechnology • Israel • Nano • NASD

Peers: REVB CNTN PALI PMCB SLXN NERV BCDA BBLG HYFT SNSE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.70	Insider Own	0.88%	Shs Outstand	1.78M	Perf Week	7.03%
Market Cap	28.23M	Forward P/E	-	EPS next Y	-	Insider Trans	-42.61%	Shs Float	1.77M	Perf Month	35.53%
Enterprise Value	15.96M	PEG	-	EPS next Q	-	Inst Own	9.88%	Short Float	3.80%	Perf Quarter	20.66%
Income	-3.34M	P/S	-	EPS this Y	-	Inst Trans	7.51%	Short Ratio	1.29	Perf Half Y	148.90%
Sales	0.00M	P/B	1.21	EPS next Y	-	ROA	-24.72%	Short Interest	0.07M	Perf YTD	86.45%
Book/sh	13.05	P/C	2.30	EPS next 5Y	-	ROE	-25.38%	52W High	2235.00 -99.29%	Perf Year	-96.60%
Cash/sh	6.88	P/FCF	-	EPS past 3/5Y	80.47% 39.74%	ROIC	-15.89%	52W Low	2.88 449.65%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.28% 12.59%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	99.51%	Oper. Margin	-	ATR (14)	1.53	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	29.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	64.24	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	29.03	EPS Q/Q	99.43%	SMA20	22.33%	Beta	-2.32	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	19.78%	Rel Volume	0.70	Prev Close	15.72
Employees	6	LT Debt/Eq	0.00	Earnings	-	SMA200	64.61%	Avg Volume	52.23K	Price	15.83
IPO	Oct 29, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	34,207	Change	0.70%

Apr-27-26 09:28AM	Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform (GlobeNewswire) +6.88%
Apr-08-26 04:16PM	Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements (GlobeNewswire)
Apr-07-26 08:00AM	Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement (GlobeNewswire) -9.92%
Mar-26-26 09:23AM	Polyrizon Provides 2025 and Recent Highlights (GlobeNewswire)
Mar-25-26 05:25PM	Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 (GlobeNewswire)
08:47AM	Loading…
Mar-24-26 08:47AM	Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications (GlobeNewswire) -5.03%
Mar-17-26 08:25AM	Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program (GlobeNewswire)
Mar-10-26 07:55AM	Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study (GlobeNewswire)
Feb-26-26 08:12AM	Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product (GlobeNewswire)
Feb-17-26 11:32AM	Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX, Drug-Free Allergy Blocker (PR Newswire)
Feb-10-26 06:55AM	Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator (GlobeNewswire)
Feb-06-26 07:55AM	Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation (GlobeNewswire)
Feb-04-26 07:12AM	Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company (GlobeNewswire) -15.16%
Jan-22-26 09:25AM	Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX Allergy Blocker (GlobeNewswire)
Jan-13-26 08:39AM	Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet (GlobeNewswire)
08:45AM	Loading…
Jan-08-26 08:45AM	Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX (GlobeNewswire) +8.36%
Jan-05-26 09:07AM	Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator (GlobeNewswire)
Jan-02-26 08:30AM	As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated (GlobeNewswire) +50.18%
Dec-29-25 07:20AM	Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet (GlobeNewswire)
Dec-19-25 08:20AM	Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses (GlobeNewswire) -6.73%
Dec-11-25 08:15AM	Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program (GlobeNewswire) +11.46%
Dec-08-25 08:55AM	Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray (GlobeNewswire) -15.65%
Dec-05-25 10:26AM	This Former Penny Stock Just Doubled for the Second Time This Week. Should You Chase the Rally Here? (Barchart) -9.66%
Dec-04-25 07:32AM	From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection (GlobeNewswire) +104.51%
Dec-03-25 09:28AM	Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product (GlobeNewswire)
Dec-02-25 07:55AM	Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform (GlobeNewswire) +131.96%
Nov-06-25 08:55AM	Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation (GlobeNewswire) -5.31%
Oct-06-25 08:21AM	Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy (GlobeNewswire)
Sep-19-25 08:15AM	Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker (GlobeNewswire) +7.69%
Sep-12-25 07:26AM	Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study (GlobeNewswire) +22.76%
08:14AM	Loading…
Aug-14-25 08:14AM	Polyrizon Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.89%
Jul-23-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +29.66%
Jul-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +59.73%
08:32AM	Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study (GlobeNewswire)
Jul-15-25 07:55AM	Polyrizon Retains Nasdaq Listing Following Hearings Panel (GlobeNewswire) +52.47%
Jun-12-25 07:32AM	Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics (GlobeNewswire) +33.75%
May-23-25 04:15PM	Polyrizon Announces Receipt of Nasdaq Delisting Notice (GlobeNewswire) -19.05% -24.00%
May-21-25 07:10AM	Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform (GlobeNewswire)
May-13-25 07:45AM	Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment (GlobeNewswire) -91.86%
May-03-25 11:00AM	Ford, Disney, And AMD To Report Results Next Week (Seeking Alpha)
Apr-25-25 07:37AM	Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model (GlobeNewswire)
Apr-11-25 04:15PM	Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements (GlobeNewswire) +6.04%
Apr-02-25 09:05AM	Polyrizon Engages Leading Branding Firm for Strategic Brand Development (GlobeNewswire) +7.52%
Apr-01-25 04:09PM	Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement (GlobeNewswire)
Mar-31-25 09:32AM	Polyrizon Ltd. Announces $17.0 Million Private Placement (GlobeNewswire) -22.93%
Mar-27-25 08:25AM	Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting (GlobeNewswire) +6.09%
Mar-25-25 04:04PM	Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment (GlobeNewswire) -27.95% -12.96%
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-19-25 07:35AM	Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination (GlobeNewswire)
Mar-14-25 08:35AM	Polyrizon Signs Non Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments (GlobeNewswire) -17.65%
Mar-13-25 07:51AM	Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform (GlobeNewswire)
Mar-11-25 04:27PM	Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 (GlobeNewswire) -6.25% -6.27%
Mar-10-25 07:47AM	Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform (GlobeNewswire)
Jan-30-25 05:55AM	Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target (T&T) Intranasal Drug Delivery Platform (GlobeNewswire)
Jan-23-25 06:40AM	Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial (GlobeNewswire) -5.41%
Dec-30-24 06:25AM	Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies (GlobeNewswire) +31.71%
Dec-19-24 07:22AM	Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs (GlobeNewswire) -29.18%
Dec-18-24 06:25AM	Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker (GlobeNewswire) +213.33%
Dec-13-24 06:25AM	Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance (GlobeNewswire)
Dec-02-24 08:02AM	Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial (GlobeNewswire) +30.13%
Oct-30-24 01:50PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ) (ACCESSWIRE) +8.39%
10:28AM	Polyrizon Announces Closing of $4.2 Million Initial Public Offering (GlobeNewswire)

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Izraeli Tomer	Chief Executive Officer	Mar 31 '26	Sale	11.85	500	5,925	31,512	Apr 01 04:15 PM
Carmel Liron	Director	Mar 31 '26	Sale	12.36	942	11,643	3,127	Apr 01 04:15 PM
Adler Oz	Director	Mar 31 '26	Sale	12.05	3,292	39,669	19,850	Apr 01 04:15 PM
Carmel Liron	Director	Mar 30 '26	Sale	11.00	100	1,100	4,069	Mar 31 04:17 PM
Izraeli Tomer	Chief Executive Officer	Mar 30 '26	Sale	10.90	3,900	42,510	32,012	Mar 31 04:17 PM
Turgeman Tidhar	Chief Technology Officer	Mar 30 '26	Sale	10.90	2,917	31,795	17,518	Mar 31 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLRZ

Polyrizon Ltd

Upgrade your Finviz experience